| | 5300-03-8 Basic information More.. |
| Product Name: | 9-CIS-RETINOIC ACID | | Synonyms: | RETINOIC ACID, 9-CIS-;RARECHEM AL BE 0738;(2E,4E,6Z,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-ENYL)NONA-2,4,6,8-TETRAENOIC ACID;9-CIS-RETINOIC ACID;9-CIS-TRETINOIN;9-cis-tretinoi;3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-t;ALIRETINOIN | | CAS: | 5300-03-8 | | MF: | C20H28O2 | | MW: | 300.44 | | EINECS: | 1533716-785-6 | | Mol File: | 5300-03-8.mol |  |
Use
Alitretinoin was introduced in the US for the topical treatment of
cutaneous lesions in patients with Kaposi's sarcoma (KS), the most frequent
malignancy observed in AIDS patients. It is a derivative of 9-cis-retinoic acid (9-
cis-RA) identified as an endogenous hormone in mammalian tissues. Alitretinoin
binds to all isoforms of the intracellular retinoid X (RXR) and retinoid A (RAR)
receptors thus inducing cell differentiation, increasing cell apoptosis and
inhibiting cellular proliferation in experimental models of human cancer. In an
international phase III trial in patients with KS, 42% of 82 patients treated with
0.1% gel formulation experienced complete or partial responses cf 7% for
controls. Alitretinoin is the first topical therapy for KS and is expected to be a
new option to its traditional management.
- 9-cis-Retinoic Acid
-
- US $78.00-198.00 / mg
- 2024-11-12
- CAS:5300-03-8
- Min. Order:
- Purity: ≥98%
- Supply Ability: 10g
- 9-cis-Retinoic Acid
-
- US $30.00-10.00 / KG
- 2024-11-04
- CAS:5300-03-8
- Min. Order: 50KG
- Purity: 99%
- Supply Ability: 500000kg
- 9-cis-Retinoic Acid
-
- US $0.00 / KG
- 2023-10-16
- CAS:5300-03-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
|
|
5300-03-8
Recommend Suppliers |
|